學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Jiuding Capital: Private Equity Firm with Chinese Characteristics (B)
內容大綱
Established in 2007, JD Capital was able to quickly gain a strong foothold in the Chinese private equity (PE) market by massively investing in pre-IPO deals and taking advantage of the high valuation offered by the ChiNext Board. JD Capital has engaged in a "factory-style" operational model. The firm has approximately 60 branch locations across China with more than 300 employees, where each local office is responsible for local deal sourcing and for strengthening communications with local governments, banks, and securities firms. Chinese private equity market has experienced drastic changes since 2012. The issuance of new IPOs slowed down and was later suspended, the opportunities for exit have greatly narrowed, and the raised funds have rapidly decreased. JD Capital's early success had enabled it to obtain a large portfolio of deals, most of which are pre-IPO projects, the slowdown and suspension of IPOs imposed serious exit challenges. Can JD Capital's past investment strategy and business model continue to be effective? Is listing on the New OTC Board a lifesaving solution? As China's capital market has become more mature, how should JD Capital transform itself to stay competitive in the industry?